

Gelareh Zadeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5572125/publications.pdf>

Version: 2024-02-01

213
papers

7,145
citations

57758

44
h-index

76900

74
g-index

219
all docs

219
docs citations

219
times ranked

10296
citing authors

#	ARTICLE	IF	CITATIONS
1	BAP1-deficient meningioma presenting with trabecular architecture and cytokeratin expression: a report of two cases and review of the literature. <i>Journal of Clinical Pathology</i> , 2023, 76, 315-319.	2.0	4
2	Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. <i>Neuro-Oncology</i> , 2022, 24, 571-581.	1.2	39
3	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	1.2	83
4	DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma. <i>Neuro-Oncology</i> , 2022, 24, 442-454.	1.2	21
5	Central Nervous System Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 161-188.	2.2	10
6	Real-time synchronized recording of force and position data during a mastoidectomy “ Toward robotic mastoidectomy development. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2022, 27, 101439.	0.3	0
7	Outcomes in vestibular schwannoma treated with primary microsurgery: Clinical landscape. <i>Journal of Clinical Neuroscience</i> , 2022, 96, 138-146.	1.5	3
8	Consensus core clinical data elements for meningiomas (v2021.1). <i>Neuro-Oncology</i> , 2022, 24, 683-693.	1.2	7
9	Perspective review on applications of optics in skull base surgery. <i>Clinical Neurology and Neurosurgery</i> , 2022, 212, 107085.	1.4	1
10	Untapped Neuroimaging Tools for Neuro-Oncology: Connectomics and Spatial Transcriptomics. <i>Cancers</i> , 2022, 14, 464.	3.7	9
11	Long-term neurocognitive, psychological, and return to work outcomes in meningioma patients. <i>Supportive Care in Cancer</i> , 2022, 30, 3893-3902.	2.2	10
12	Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. <i>Neurosurgery</i> , 2022, 90, 140-147.	1.1	10
13	Multiplicity does not significantly affect outcomes in brain metastasis patients treated with surgery. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac022.	0.7	3
14	Radiation dose to circumscribed brain regions and neurocognitive function in patients with meningioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 208-218.	1.6	1
15	Endoscopic Treatment of Sellar Arachnoid Cysts via a Simple Cyst-Opening Technique: Long-Term Outcomes From a Single Center. <i>World Neurosurgery</i> , 2022, 161, e625-e634.	1.3	3
16	Endoscopic Endonasal Surgery for Prolactinomas: Prognostic Factors for Disease Control and Management of Persistent Disease. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, .	0.8	0
17	Opportunities and challenges for the development of “core outcome sets” in neuro-oncology. <i>Neuro-Oncology</i> , 2022, 24, 1048-1055.	1.2	5
18	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes. <i>Nature Communications</i> , 2022, 13, 1811.	12.8	21

#	ARTICLE	IF	CITATIONS
19	Factors correlating with survival following adjuvant or definitive radiosurgery for large brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 1925-1934.	1.2	4
20	Development of "Core Outcome Sets"™ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings. <i>BMJ Open</i> , 2022, 12, e057384.	1.9	7
21	Barriers and facilitators in the implementation of a telemedicine-based outpatient brain tumor surgery program. <i>Neurosurgical Focus</i> , 2022, 52, E8.	2.3	0
22	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211096.	1.9	9
23	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. <i>Acta Neuropathologica</i> , 2021, 141, 101-116.	7.7	26
24	Brain Metastases: A Modern Multidisciplinary Approach. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 189-197.	0.5	8
25	Psychometric testing of the Skull Base Inventory health-related quality of life questionnaire in a multi-institutional study of patients undergoing open and endoscopic surgery. <i>Quality of Life Research</i> , 2021, 30, 293-301.	3.1	6
26	Malignant transformation of plexiform neurofibroma to MPNST while on MEK inhibitor. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab033.	0.7	2
27	Predictors of survival in elderly patients undergoing surgery for glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab083.	0.7	7
28	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 1 newly diagnosed disease. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab028.	0.7	4
29	Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients. <i>Current Oncology</i> , 2021, 28, 549-559.	2.2	10
30	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021, 23, 506-507.	1.2	0
31	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab029.	0.7	1
32	A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa176.	0.7	1
33	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab035.	0.7	3
34	Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. <i>Journal of Neuro-Oncology</i> , 2021, 151, 443-449.	2.9	13
35	Cross-sectional analysis of women in neurosurgery: a Canadian perspective. <i>Neurosurgical Focus</i> , 2021, 50, E13.	2.3	10
36	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47

#	ARTICLE	IF	CITATIONS
37	Surgical anatomy and technical nuances of the endoscopic endonasal approach to the anterior cranial fossa. <i>Journal of Neurosurgical Sciences</i> , 2021, 65, 103-117.	0.6	8
38	TNF \pm secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 67.	5.2	28
39	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. <i>Neuro-Oncology</i> , 2021, 23, 1252-1260.	1.2	11
40	Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4548.	4.1	22
41	Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. <i>Neurosurgery</i> , 2021, 89, 196-203.	1.1	2
42	Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14026-e14026.	1.6	6
43	Development and validation of a patient-centered, meningioma-specific quality-of-life questionnaire. <i>Journal of Neurosurgery</i> , 2021, 135, 1685-1694.	1.6	5
44	Loss of H3K27me3 in meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1282-1291.	1.2	45
45	Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 34-39.	2.0	6
46	MLTI-06. Surgical resection plus stereotactic radiosurgery versus SRS alone for large brain metastases: a comparative study. <i>Neuro-Oncology Advances</i> , 2021, 3, iii14-iii14.	0.7	0
47	Radiation Dose Rate, Biologically Effective Dose, and Tumor Characteristics on Local Control and Toxicity After Radiosurgery for Acoustic Neuromas. <i>World Neurosurgery</i> , 2021, 152, e512-e522.	1.3	8
48	A clinically applicable integrative molecular classification of meningiomas. <i>Nature</i> , 2021, 597, 119-125.	27.8	180
49	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. <i>Journal of Neuro-Oncology</i> , 2021, 155, 63-70.	2.9	6
50	Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. <i>Neuro-Oncology</i> , 2021, 23, 795-802.	1.2	3
51	The centrally restricted diffusion sign on MRI for assessment of radiation necrosis in metastases treated with stereotactic radiosurgery. <i>Journal of Neuro-Oncology</i> , 2021, 155, 325-333.	2.9	8
52	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
53	Incidence and prevalence of primary malignant brain tumours in Canada from 1992 to 2017: an epidemiologic study. <i>CMAJ Open</i> , 2021, 9, E973-E979.	2.4	8
54	A Phase II Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases: Clinical Trial Protocol. <i>Neurosurgery</i> , 2020, 87, 403-407.	1.1	15

#	ARTICLE	IF	CITATIONS
55	Rare IDH1 variants are common in pediatric hemispheric diffuse astrocytomas and frequently associated with Li-Fraumeni syndrome. <i>Acta Neuropathologica</i> , 2020, 139, 795-797.	7.7	7
56	Reinitiation of Anticoagulation After Surgical Evacuation of Subdural Hematomas. <i>World Neurosurgery</i> , 2020, 135, e616-e622.	1.3	7
57	How should we manage incidental meningiomas?. <i>Neuro-Oncology</i> , 2020, 22, 173-174.	1.2	3
58	Brain tumors and COVID-19: the patient and caregiver experience*. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa104.	0.7	17
59	Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa111.	0.7	24
60	Clinical value of methylation testing: a case report of intraventricular schwannomas with associated molecular findings. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa029.	0.7	1
61	How to live with a meningioma: experiences, symptoms, and challenges reported by patients. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa086.	0.7	3
62	Current Results of Surgical Treatment of Craniopharyngiomas: The Impact of Endoscopic Endonasal Approaches. <i>World Neurosurgery</i> , 2020, 142, 582-592.	1.3	23
63	Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression. <i>Scientific Reports</i> , 2020, 10, 14115.	3.3	20
64	Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. <i>Neuro-Oncology Advances</i> , 2020, 2, i141-i149.	0.7	18
65	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	5.5	18
66	Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1044-1047.	30.7	170
67	COVID-19 Testing in Patients with Cancer: Does One Size Fit All?. <i>Clinical Cancer Research</i> , 2020, 26, 4737-4742.	7.0	23
68	NCI-CONNECT rare CNS tumor initiative: current progress and anticipated future impact. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa022.	0.7	2
69	Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2664-2672.	7.0	21
70	Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. <i>Journal of Neuro-Oncology</i> , 2020, 147, 525-529.	2.9	76
71	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1474-1483.	1.2	39
72	c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. <i>Molecular Cancer Research</i> , 2020, 18, 774-786.	3.4	10

#	ARTICLE	IF	CITATIONS
73	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
74	LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). <i>Neuro-Oncology</i> , 2020, 22, ii237-ii237.	1.2	21
75	Artificial Intelligence, Radiomics, and Deep Learning in Neuro-Oncology. <i>Neuro-Oncology Advances</i> , 2020, 2, iv1-iv2.	0.7	7
76	The Importance of Long Term Follow Up After Endoscopic Pituitary Surgery: Durability of Results and Tumor Recurrence. <i>Neurology India</i> , 2020, 68, 92.	0.4	8
77	Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3167-TPS3167.	1.6	2
78	Short Course Hypofractionated Radiotherapy for Frail or Elderly Patients With Meningioma. <i>Cureus</i> , 2020, 12, e8604.	0.5	0
79	Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. <i>Pituitary</i> , 2019, 22, 514-519.	2.9	28
80	Pituitary Apoplexy: Results of Surgical and Conservative Management Clinical Series and Review of the Literature. <i>World Neurosurgery</i> , 2019, 130, e988-e999.	1.3	46
81	Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. <i>Clinical Genetics</i> , 2019, 96, 461-467.	2.0	16
82	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. <i>Acta Neuropathologica</i> , 2019, 138, 1053-1074.	7.7	106
83	Hypoxia Can Induce Migration of Glioblastoma Cells Through a Methylation-Dependent Control of ODZ1 Gene Expression. <i>Frontiers in Oncology</i> , 2019, 9, 1036.	2.8	13
84	Evidence of small fiber neuropathy in neurofibromatosis type 1. <i>Muscle and Nerve</i> , 2019, 60, 673-678.	2.2	9
85	Highlights of the inaugural ten – the launch of <i>Neuro-Oncology Advances</i> . <i>Neuro-Oncology Advances</i> , 2019, 1, vdz016.	0.7	0
86	Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells. <i>Journal of Oncology</i> , 2019, 2019, 1-16.	1.3	46
87	Recurrent Undifferentiated Carcinoma of the Sella in a Patient with Lynch Syndrome. <i>World Neurosurgery</i> , 2019, 132, 219-222.	1.3	5
88	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	1.2	102
89	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
90	Proteomic analysis of meningiomas reveals clinically distinct molecular patterns. <i>Neuro-Oncology</i> , 2019, 21, 1028-1038.	1.2	42

#	ARTICLE	IF	CITATIONS
91	Needle in a haystack: identifying drivers of malignant transformation in neurofibromas. <i>Neuro-Oncology</i> , 2019, 21, 961-962.	1.2	0
92	A dural-based spindle cell neoplasm characterized by a novel MN1-KMT2A fusion gene. <i>Neuro-Oncology</i> , 2019, 21, 1082-1083.	1.2	3
93	CIC protein instability contributes to tumorigenesis in glioblastoma. <i>Nature Communications</i> , 2019, 10, 661.	12.8	63
94	Expanded Endonasal Endoscopic Surgery in Suprasellar Craniopharyngiomas: A Retrospective Analysis of 43 Surgeries Including Recurrent Cases. <i>Operative Neurosurgery</i> , 2019, 17, 132-142.	0.8	26
95	Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 3366-3373.	7.0	17
96	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
97	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. <i>Clinical Epigenetics</i> , 2019, 11, 185.	4.1	51
98	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178.	1.2	173
99	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. <i>Neuro-Oncology</i> , 2019, 21, i32-i43.	1.2	56
100	Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i4-i17.	1.2	92
101	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	1.2	69
102	Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose. <i>Neuro-Oncology</i> , 2019, 21, 242-251.	1.2	27
103	Tuberculum sellae meningiomas: a systematic review of transcranial approaches in the endoscopic era. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 200-215.	0.6	12
104	Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis. <i>Journal of Clinical Oncology</i> , 2019, 37, e20574-e20574.	1.6	0
105	Extended Endoscopic Approach for Resection of Craniopharyngiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S201-S202.	0.8	4
106	Management and Outcomes in the Oldest-Old Population with Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 199-205.	0.5	10
107	The multiforme of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 437-438.	1.2	3
108	Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital. <i>Journal of Neurosurgery</i> , 2018, 128, 1226-1234.	1.6	57

#	ARTICLE	IF	CITATIONS
109	Management of multiple meningiomas. <i>Journal of Neurosurgery</i> , 2018, 128, 1403-1409.	1.6	31
110	GENE-09. FUNCTIONAL GENOMIC ELEMENTS DEFINED BY DNA METHYLATION CAN DISTINGUISH MENINGIOMA SUBGROUPS. <i>Neuro-Oncology</i> , 2018, 20, vi104-vi104.	1.2	0
111	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 223-229.	8.2	130
112	GENE-26. MOLECULAR CHARACTERIZATION OF BENIGN AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS THAT OCCUR IN SPORADIC AND SYNDROMIC SETTINGS. <i>Neuro-Oncology</i> , 2018, 20, vi108-vi109.	1.2	0
113	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 148-157.	3.8	2
114	ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). <i>Neuro-Oncology</i> , 2018, 20, vi6-vi6.	1.2	27
115	TMIC-07. HYPOXIC MICROENVIRONMENT CONFERS SPECIFIC ALTERATIONS IN DNA METHYLATION PROFILES IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi257-vi257.	1.2	0
116	CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA <i>IN VITRO</i> AND <i>IN VIVO</i> . <i>Neuro-Oncology</i> , 2018, 20, vi282-vi282.	1.2	0
117	PATH-25. SURVIVAL STRATIFICATION OF IDH MUTANT GLIOMA USING METHYLATION AND mRNA ANALYSIS OF HOX GENES. <i>Neuro-Oncology</i> , 2018, 20, vi163-vi164.	1.2	0
118	RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi235.	1.2	0
119	RTHP-07. TRANSCRIPTION FACTOR NETWORKS OF OLIGODENDROGLIOMAS (IDH-MUTANT AND 1p/19q) Tj ETQq1 1 0.784314 rgBT /Ox <i>Neuro-Oncology</i> , 2018, 20, vi226-vi226.	1.2	0
120	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi106-vi107.	1.2	0
121	TMOD-02. DIFFUSE GLIOMATOSIS IN MOUSE MODEL OF GFAP TISSUE SPECIFIC KNOCK IN OF EGFR ^{III} AND KNOCK OUT OF p19 ARF. <i>Neuro-Oncology</i> , 2018, 20, vi268-vi268.	1.2	0
122	MNGI-12. EXPRESSION OF PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) IN MENINGIOMA: CLINICAL UTILITY FOR PREDICTION OF TUMOR RECURRENCE AND ASSOCIATION WITH HYPOXIC RESPONSE AND NFKB2 ACTIVATION. <i>Neuro-Oncology</i> , 2018, 20, vi150-vi151.	1.2	0
123	MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE. <i>Neuro-Oncology</i> , 2018, 20, vi148-vi149.	1.2	0
124	GENE-08. SCHWANNOMATOSIS SCHWANNOMAS HARBOR DISTINCT DNA METHYLATION PROFILES. <i>Neuro-Oncology</i> , 2018, 20, vi104-vi104.	1.2	0
125	CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi33-vi33.	1.2	0
126	GENE-05. UPREGULATION OF ODZ1-MEDIATED INVASION IN THE HYPOXIC TUMOR MICROENVIRONMENT IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi103-vi103.	1.2	0

#	ARTICLE	IF	CITATIONS
127	TMIC-17. IMMUNE MICROENVIRONMENT OF NF2-ALTERED RADIATION-INDUCED MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi259-vi259.	1.2	1
128	Endoscopic management of Esthesioneuroblastoma: Our experience and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2018, 58, 117-123.	1.5	10
129	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	2.0	42
130	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. <i>Acta Neuropathologica</i> , 2017, 133, 431-444.	7.7	155
131	Radiosurgery for brainstem metastases with and without whole brain radiotherapy: clinical series and literature review. <i>Journal of Radiation Oncology</i> , 2017, 6, 21-30.	0.7	13
132	One and a half syndrome following penetrating head injury: Case report. <i>Journal of Clinical Neuroscience</i> , 2017, 41, 88-90.	1.5	3
133	Preferences and Utilities for Health States after Treatment of Olfactory Groove Meningioma: Endoscopic versus Open. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, 315-323.	0.8	3
134	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	7.7	26
135	Citation classics in neuro-oncology: assessment of historical trends and scientific progress. <i>Neuro-Oncology</i> , 2017, 19, 1158-1172.	1.2	24
136	Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1503-1510.	1.2	18
137	PET imaging in patients with meningioma—report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017, 19, 1576-1587.	1.2	157
138	National Perspectives on the Training of Neurosurgery Residents in Stereotactic Radiosurgery. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 51-58.	0.5	8
139	Molecular Signatures for Tumor Classification. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 881-891.	2.8	22
140	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. <i>Nature Communications</i> , 2017, 8, 186.	12.8	76
141	Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care. <i>Npj Precision Oncology</i> , 2017, 1, 22.	5.4	127
142	TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica. <i>Endocrine Pathology</i> , 2017, 28, 22-26.	9.0	9
143	Current Management of Brain Metastases: Overview and Teaching Cases. , 2017, , .		3
144	Quantitative comparison of cranial approaches in the anatomy laboratory: A neuronavigation based research method. <i>World Journal of Methodology</i> , 2017, 7, 139-147.	3.5	15

#	ARTICLE	IF	CITATIONS
145	Quantification and Comparison of Neurosurgical Approaches in the Anatomy Laboratory: Description and Validation of a Novel, Navigation-based Method. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.8	0
146	Predictive Factors for Recurrence Following Endoscopic Treatment of Cushing's Disease. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.8	0
147	GENT-37. THE GENETICS DRIVING RADIATION INDUCED MENINGIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi82-vi82.	1.2	0
148	Management and outcome of recurrent adult craniopharyngiomas: an analysis of 42 cases with long-term follow-up. <i>Neurosurgical Focus</i> , 2016, 41, E11.	2.3	27
149	PIK3CA mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 603-604.	1.2	7
150	The Use of Cone Beam Computed Tomography for Image Guided Gamma Knife Stereotactic Radiosurgery: Initial Clinical Evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 214-220.	0.8	30
151	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. <i>Neuro-Oncology</i> , 2016, 19, now181.	1.2	17
152	The genomic landscape of schwannoma. <i>Nature Genetics</i> , 2016, 48, 1339-1348.	21.4	124
153	Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes. <i>Endocrinology</i> , 2016, 157, 3577-3587.	2.8	9
154	Atypical meningiomaâ€”is it time to standardize surgical sampling techniques?. <i>Neuro-Oncology</i> , 2016, 19, now245.	1.2	18
155	MNGO-18. MANAGEMENT OF MULTIPLE MENINGIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi105-vi105.	1.2	0
156	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. <i>Cancer Research</i> , 2016, 76, 4708-4719.	0.9	107
157	Bringing IDH into the Fold. <i>Cancer Cell</i> , 2016, 29, 139-140.	16.8	2
158	Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey. <i>Journal of Neuro-Oncology</i> , 2016, 126, 137-149.	2.9	16
159	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. <i>Modern Pathology</i> , 2016, 29, 131-142.	5.5	114
160	Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. <i>Neuro-Oncology</i> , 2016, 18, 160-172.	1.2	214
161	DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma. <i>Oncotarget</i> , 2016, 7, 56431-56446.	1.8	5
162	Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. <i>Oncotarget</i> , 2016, 7, 69518-69535.	1.8	51

#	ARTICLE	IF	CITATIONS
163	Much debated controversies of diffuse low-grade gliomas. <i>Neuro-Oncology</i> , 2015, 17, 323-326.	1.2	8
164	A role for matrix remodelling proteins in invasive and malignant meningiomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, e16-28.	3.2	14
165	Postoperative Copeptin Concentration Predicts Diabetes Insipidus After Pituitary Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2275-2282.	3.6	67
166	Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance. <i>Journal of Neurosurgery</i> , 2015, 122, 1360-1369.	1.6	166
167	IMCT-04TOCA 5: PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 WITH TOCA FC VERSUS STANDARD OF CARE IN PATIENTS UNDERGOING PLANNED RESECTION FOR RECURRENT HIGH GRADE GLIOMA (NCT02414165). <i>Neuro-Oncology</i> , 2015, 17, v107.4-v108.	1.2	0
168	Serum lactate as a potential biomarker of malignancy in primary adult brain tumours. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 144-148.	1.5	31
169	Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. <i>Neuro-Oncology</i> , 2015, 17, 889-894.	1.2	93
170	Localized Intraoperative Virtual Endoscopy (LIVE) for Surgical Guidance in 16 Skull Base Patients. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 152, 165-171.	1.9	16
171	Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics. <i>Endocrine Pathology</i> , 2015, 26, 63-70.	9.0	59
172	High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery. <i>Neuro-Oncology</i> , 2015, 17, nov113.	1.2	51
173	Endoscopic Endonasal Repair of Spontaneous and Traumatic Cerebrospinal Fluid Rhinorrhea. <i>Neurosurgery Clinics of North America</i> , 2015, 26, 333-348.	1.7	16
174	A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 471-480.	2.9	6
175	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015, 21, 3750-3758.	7.0	40
176	Serum lactate as a potential biomarker of non-gliar brain tumors. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1625-1627.	1.5	28
177	Neddylation in glioblastomas. <i>Neuro-Oncology</i> , 2015, 17, 1305-1306.	1.2	5
178	Comparison of endoscopic endonasal and bifrontal craniotomy approaches for olfactory groove meningiomas: A matched pair analysis of outcomes and frontal lobe changes on MRI. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1733-1741.	1.5	55
179	Predictors of response to Gamma Knife radiosurgery for intracranial meningiomas. <i>Journal of Neurosurgery</i> , 2015, 123, 1294-1300.	1.6	20
180	Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. <i>Nature Communications</i> , 2015, 6, 8859.	12.8	173

#	ARTICLE	IF	CITATIONS
181	Identifying Predictors of Early Growth Response and Adverse Radiation Effects of Vestibular Schwannomas to Radiosurgery. <i>PLoS ONE</i> , 2014, 9, e110823.	2.5	6
182	MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. <i>Neuro-Oncology</i> , 2014, 16, 868-879.	1.2	39
183	The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence. <i>International Journal of Molecular Sciences</i> , 2014, 15, 11832-11846.	4.1	183
184	The Evolving Role of Radiosurgery in the Management of Radiation-Induced Meningiomas: A Review of Current Advances and Future Directions. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	6
185	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. <i>Cancer Discovery</i> , 2014, 4, 1198-1213.	9.4	55
186	AI-02 * HYPOXIA AS A MEASURE OF FUNCTIONAL STATUS OF GLIOBLASTOMA VASCULATURE. <i>Neuro-Oncology</i> , 2014, 16, v1-v1.	1.2	0
187	From Craniofacial Resection to Endonasal Endoscopic Removal of Malignant Tumors of the Anterior Skull Base. <i>World Neurosurgery</i> , 2014, 82, S59-S65.	1.3	23
188	Pure endoscopic expanded endonasal approach for olfactory groove and tuberculum sellae meningiomas. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 927-933.	1.5	41
189	Growth Patterns of Pituitary Adenomas and Histopathological Correlates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1330-1338.	3.6	40
190	GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. <i>Neuro-Oncology</i> , 2014, 16, 1167-1175.	1.2	125
191	Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3785-94.	7.1	81
192	Salvage Radiosurgery for Brain Metastases: Prognostic Factors to Consider in Patient Selection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 137-142.	0.8	48
193	VEGF Regulates Region-Specific Localization of Perivascular Bone Marrow-Derived Cells in Glioblastoma. <i>Cancer Research</i> , 2014, 74, 3727-3739.	0.9	23
194	Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: Potential for targeting experimental brain tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e1075-e1087.	3.3	77
195	Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. <i>Oncotarget</i> , 2014, 5, 9382-9395.	1.8	37
196	Proteins involved in regulating bone invasion in skull base meningiomas. <i>Acta Neurochirurgica</i> , 2013, 155, 421-427.	1.7	24
197	Imaging Biomarker Dynamics in an Intracranial Murine Glioma Study of Radiation and Antiangiogenic Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 805-812.	0.8	30
198	EGFR and EGFRvIII in Glioblastoma: Partners in Crime. <i>Cancer Cell</i> , 2013, 24, 403-404.	16.8	47

#	ARTICLE	IF	CITATIONS
199	Endonasal Endoscopic Release of a Delayed Tension Pneumocephalus After Craniofacial Resection of a Tumor of the Anterior Skull Base. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2013, 74, e271-e274.	0.8	5
200	A microRNA Link to Glioblastoma Heterogeneity. <i>Cancers</i> , 2012, 4, 846-872.	3.7	15
201	Clinical features of silent corticotroph adenomas. <i>Acta Neurochirurgica</i> , 2012, 154, 1493-1498.	1.7	59
202	High-Resolution In-Vivo Analysis of Normal Brain Response to Cranial Irradiation. <i>PLoS ONE</i> , 2012, 7, e38366.	2.5	45
203	Diagnostic implications of histological analysis of neurosurgical aspirate in addition to routine resections. <i>Neuropathology</i> , 2012, 32, 44-50.	1.2	6
204	Trigeminal nerve integrated dose and pain outcome after gamma knife radiosurgery for trigeminal neuralgia. <i>Journal of Radiosurgery and SBRT</i> , 2012, 1, 295-301.	0.2	3
205	Role of Angiopoietin-2 in Regulating Growth and Vascularity of Astrocytomas. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	1.3	15
206	Radiation induced peripheral nerve tumors: case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2007, 83, 205-212.	2.9	19
207	Regulation of the Pathological Vasculature of Malignant Astrocytomas by Angiopoietin-1. <i>Neoplasia</i> , 2005, 7, 1081-1090.	5.3	20
208	Role of Ang1 and Its Interaction with VEGF-A in Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 978-989.	1.7	29
209	Targeting the Tie2/Tek Receptor in Astrocytomas. <i>American Journal of Pathology</i> , 2004, 164, 467-476.	3.8	55
210	Angiogenesis in Nervous System Disorders. <i>Neurosurgery</i> , 2003, 53, 1362-1376.	1.1	62
211	Neoangiogenesis in human astrocytomas expression and functional role of angiopoietins and their cognate receptors. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, e128-137.	3.0	22
212	Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors (review). <i>International Journal of Oncology</i> , 2003, 23, 557-65.	3.3	10
213	Brain tumour patients and COVID-19 vaccines: results of an international survey. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	1